Senseonics Receives European Approval for Eversense 365, World’s Longest-lasting Continuous Glucose Monitor
SENSGERMANTOWN, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced CE Mark approval for the Eversense® 365 CGM system.
Senseonics Holdings, Inc. to Participate in the Stifel 2025 Healthcare Conference
SENSGERMANTOWN, Md., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Stifel 2025 Healthcare Conference, being held in New York, NY.
Senseonics Signs Memorandum of Understanding with Ascensia Diabetes Care to Take Over Commercialization and Distribution of Eversense 365
SENS(SENS) CGM commercial operations to transition from Ascensia Diabetes Care to Senseonics
Senseonics Holdings, Inc. Reports Second Quarter Financial Results
SENSGenerated Q2 revenue of $6.6 million, representing year-over-year growth of 37%
HC Wainwright & Co. Assumes Senseonics Holdings at Buy, Announces Price Target of $1.1
SENSReported Earlier, Senseonics Prices $50M Public Offering Of 100M Common Shares At $0.50 Per Share
SENSSenseonics Commences $50M Public Offering Of Common Stock And Concurrent Private Placement
SENSSenseonics Holdings Affirms FY2025 Sales Guidance of $34.00M-$38.00M vs $35.28M Est
SENSSenseonics Holdings Q1 EPS $(0.02), Inline, Sales $6.26M Beat $5.56M Estimate
SENSSenseonics Holdings's Earnings: A Preview
SENSSequel Med Tech Inks Commercial Development Agreement With Senseonics To Integrate Sequel's twiist Automated Insulin Delivery (AID)
SENSMizuho Initiates Coverage On Senseonics Holdings with Outperform Rating, Announces Price Target of $2
SENSHC Wainwright & Co. Reiterates Buy on Senseonics Holdings, Maintains $2 Price Target
SENSSenseonics Holdings Sees FY25 Revenue $34M-$38M
SENSSenseonics Holdings Q4 2024 GAAP EPS $(0.03), Inline, Sales $8.30M Beat $7.86M Estimate
SENSSenseonics And Ascensia Expand Diabetes Management Capabilities By Integrating SweetSpot With Eversense 365 CGM System
SENSReported Earlier, Senseonics Reports $22.5M Preliminary 2024 Revenue With $8.4M In Q4, 56% YoY Patient Growth, And Milestone Eversense 365 Launch Success
SENSHC Wainwright & Co. Reiterates Buy on Senseonics Holdings, Maintains $2 Price Target
SENS